460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers - Concepedia

Concepedia

Publication | Open Access

460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

DOI Full Paper Access

50

Citations

0

References

2022

Year

Komal Jhaveri, Hyo S. Han, Efrat Dotan, D-Y. Oh, C. Ferrario, Anthony W. Tolcher, Kyung-Woo Lee, C-Y. Liao, Y-K. Kang, Yeul Hong Kim,

Annals of Oncology

Abstract

title: Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers, doi: 10.1016/j.annonc.2022.07.589, category: Article